Back Pain - Pipeline Review, Q1 2011

Global Markets Direct, March 2011, Pages: 49

Back Pain - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Back Pain - Pipeline Review, Q1 2011', provides an overview of the Back Pain therapeutic pipeline. This report provides information on the therapeutic development for Back Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Back Pain. 'Back Pain - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Back Pain.
- A review of the Back Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Back Pain pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Back Pain.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Back Pain pipeline depth and focus of Back Pain therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Back Pain Overview
Therapeutics Development
An Overview of Pipeline Products for Back Pain
Back Pain Therapeutics under Development by Companies
Back Pain Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Back Pain Therapeutics - Products under Development by Companies
Back Pain Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Back Pain Therapeutics Development
Johnson & Johnson
AstraZeneca PLC
BioDelivery Sciences International, Inc.
Endo Pharmaceuticals Holdings Inc.
Cephalon, Inc.
Hisamitsu Pharmaceutical Co., Inc.
Regeneron Pharmaceuticals, Inc.
Sosei Group Corporation
Newron Pharmaceuticals S.p.A.
Indena S.p.A.
QRxPharma Limited
Back Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
CEP-33237 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BEMA Buprenorphine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ralfinamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HKT-500 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biostat Biologx Fibrin Sealant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNS013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Sulfasalazine + Methotrexate + Hydroxychloroquine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sulfasalazine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Back Pain Therapeutics - Discontinued Products
Back Pain - Featured News
Aug 30, 2010: BioDelivery Sciences Reports BEMA Buprenorphine Phase II Study Results Selected For Presentation At Pain Week 2010
Mar 30, 2010: Lpath Rejects Merck KGaA's Proposal To Extend Opt-in Deadline
May 07, 2004: New Data Reveal the Analgesic Patch Lidoderm(R) May Improve Pain Intensity and Common Pain Qualities Associated with Low-Back Pain and Osteoarthritis
Dec 18, 2003: Endo Licenses EpiCept Patents for Back Pain and Commercial Rights to LidoPAIN(R) BP Product
Mar 20, 2003: Lidoderm(R) Pilot Phase IV Studies Presented at American Pain Society Meeting
Oct 14, 2002: Pamidronate May Help Improve Back Pain: Presented at ANA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Back Pain, Q1 2011
Products under Development for Back Pain – Comparative Analysis, Q1 2011
Comparative Analysis by Late Stage Development, Q1 2011
Comparative Analysis by Mid Clinical Stage Development, Q1 2011
Comparative Analysis by Early Clinical Stage Development, Q1 2011
Comparative Analysis by Pre-Clinical Stage Development, Q1 2011
Johnson & Johnson, 2011
AstraZeneca PLC, 2011
BioDelivery Sciences International, Inc., 2011
Endo Pharmaceuticals Holdings Inc., 2011
Cephalon, Inc., 2011
Hisamitsu Pharmaceutical Co., Inc., 2011
Regeneron Pharmaceuticals, Inc., 2011
Sosei Group Corporation, 2011
Newron Pharmaceuticals S.p.A., 2011
Indena S.p.A., 2011
QRxPharma Limited, 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Discontinued Products

List of Figures
Number of Products under Development for Back Pain, Q1 2011
Products under Development for Back Pain – Comparative Analysis, Q1 2011
Products under Development by Companies, Q1 2011
Products under Investigation by Universities/Institutes, Q1 2011
Late Stage Products, Q1 2011
Mid Clinical Stage Products, Q1 2011
Early Clinical Stage Products, Q1 2011
Pre-Clinical Stage Products, Q1 2011
Assessment by Monotherapy Products, Q1 2011
Assessment by Combination Products, Q1 2011
Assessment by Route of Administration, Q1 2011
Assessment by Stage and Route of Administration, Q1 2011
Assessment by Molecule Type, Q1 2011
Assessment by Stage and Molecule Type, Q1 2011

Customers who bought this item also bought

• Pain Therapeutics - Drugs, Markets and Companies
• The Top 50 Developers Of Pain Management Pharmaceuticals Worldwide
• Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
• Pain Management - Global Business Strategic Report
• Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management
• Acute Pain - Pipeline Review, H2 2012
• Osteoarthritis (OA) Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2019
• Back Pain Report 2008
• The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights
• Global Neuropathic Pain Pipeline Capsule - 2013